Back to the full story5 sources · Breakthrough' mRNA cancer drug curbs melanoma in large trial◆ Analytics
Breakthrough' mRNA cancer drug curbs melanoma in large trial
Deterministic text analytics computed across all 5 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
cancermrnatrialmodernavaccinemerckstagepersonalisedtreatmentmelanoma
Top phrases
mrna cancermrna cancer vaccinemoderna and merckcancer vaccinemoderna and merck sharespersonalised mrnacancer treatmentmerck sharescancer drugstage trial
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Moderna · 5 sources
- Merck · 4 sources
- Keytruda · 3 sources
- Merck's · 2 sources
Unique to one source
- Breakthrough · France 24
- Researchers · France 24
- Will · New Scientist
- Certain · New Scientist
- Every · New Scientist
- STAT · STAT
- Between · STAT
- Twenty · STAT
- Trump · Axios
- COVID · Axios
- Food · Axios
- Phase · Ars Technica
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "Because of that, researchers have for decades been working on personalised cancer vaccines designed to make the immune system recognise and attack cancers specific to each individual." · New Scientist
- "The results have been mixed, but now a personalised cancer vaccine has produced positive results in a final-stage trial for the first time." · New Scientist
- "Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies." · STAT
- "Twenty-four hours later, my brain is still whirling over yesterday’s stunning news from Merck and Moderna about the success of their personalized mRNA cancer therapy in a melanoma late-stage clinical trial." · STAT
- "Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial." · Axios
- "Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards." · Axios
- "The vaccine reportedly thwarted the cancer's return and spread." · Ars Technica
- "Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient's unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer." · Ars Technica